Correction to: Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors

Key Points

• Findings detail the effects of SPH4336 in treating advanced solid tumors, aiming for better outcomes.
• The trial involved multiple cohorts, evaluating a novel cyclin-dependent kinase inhibitor against traditional therapies.
• Observational analysis from the phase I trial highlights safety and tolerability of the new cancer treatment.
• The implications of this correction may enhance understanding of treatment capabilities and inform future studies.